Colchicine did not relieve knee osteoarthritis in a placebo-controlled trial

Design

Three-month double-blind, placebo-controlled randomised trial, no concurrent NSAIDs

Population

120 adults with symptomatic knee osteoarthritis, Kellgren-Lawrence grade 2 or 3

Primary outcome

Between-group change in visual analogue knee pain

Effect

No significant difference in pain, KOOS or effusion; biomarkers improved

Pharmacological options for knee osteoarthritis are thin, and colchicine's anti-inflammatory action made it a plausible candidate. This double-blind trial randomised 120 people with symptomatic knee osteoarthritis (Kellgren-Lawrence grade 2 or 3) to three months of daily colchicine or placebo, without concurrent NSAIDs.

There was no significant improvement in knee pain, function (KOOS) or ultrasound-measured effusion size. Subgroups with worse pain, worse radiographic disease, or higher inflammatory markers or urate fared no better. Colchicine did improve several inflammatory serum biomarkers, but that did not translate into symptom relief over three months.

The practical message is simply not to reach for colchicine to treat knee osteoarthritis pain. The biomarker changes leave open a hypothesis about longer-term, structure-level effects, but on the question a patient asks — does it help my knee — the answer here is no.

• No significant difference from placebo in knee pain, KOOS function scores or effusion size at three months.
• Subgroups with worse pain, worse radiographic disease or higher inflammatory markers showed no benefit either.
• Inflammatory biomarkers improved, but without any matching clinical improvement.
• Do not use colchicine to treat knee osteoarthritis pain on current evidence.

Why it matters

It closes off a tempting, cheap repurposing idea for osteoarthritis pain, at least over three months.

Don't overread it

The biomarker improvements do not establish a clinical benefit; a longer or structure-focused trial would be needed to test that hypothesis.

The statistics, in plain English

This was a clearly negative trial on its clinical endpoints: pain, function and effusion all failed to separate from placebo. The improvement in blood biomarkers without clinical change is a reminder that moving a laboratory number is not the same as helping the patient.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.